[306 Pages Report] The exonucleases market is likely to record a CAGR of 2.3% during the forecast period. The market is projected to be valued at US$ 162.6 Million in 2022 and is likely to be valued at US$ 208.1 Million by 2032.
Exonucleases are the enzymes that break nucleic acid by removing nucleotides from the end of the chain. It recognizes specific nucleotide sequences of nucleic acid and breaks the chemical bonds between nucleotides which is likely to raise the demand for exonucleases by end-user.
Exonucleases are also known as restriction endonucleases as they search for specific restriction fragments. In addition, these are the broader group of enzymes isolated from bacteria and further used for DNA fragments. They are anticipated to boost the exonucleases market growth in recent years. The market is currently growing at a low pace, acquiring decent CAGR during the foreseen time.
Report Attribute | Details |
---|---|
Exonucleases Market Value (2022) | US$ 162.6 Million |
Exonucleases Market Anticipated Value (2032) | US$ 208.1 Million |
Exonucleases Projected Growth Rate (2032) | 2.3% |
More than 100 restricted endonucleases are present in identified bacteria and archaea, which are used for commercial purposes and are likely to propel the exonucleases market growth. On the other hand, the adoption of exonucleases is rising to be used for biotechnology which plays an important role in molecular cloning. Moreover, most of these enzymes are composed of two protein subunits to wrap in the double-stranded DNA and separately cut both strands from both sides.
The sales of exonucleases are growing as these enzymes have unique recognition sites in bacteria and are involved in the repair, replication, recombination, and proper maturation and degradation of DNA and RNA. Apart from it, they cleave only at specific sequences due to their high specificity in restriction. Additionally, exonucleases are used to generate mass ladders of oligonucleotides which are analyzed with the help of mass spectroscopy. Exonucleases are identified in E Coli and human cells, driving the exonucleases market growth during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising exonucleases applications such as oligonucleotide post PCR and removal of chromosomal DNA in plasmid preparations drive the market growth. Due to controlling genetic quality, homologous combinations and repairing DNA are likely to increase the exonucleases market share during the forecast period.
Introducing new technology and development will likely increase the overall exonucleases market globally. Other factors, such as the increased use of restriction enzymes in various Research and Development activities in the molecular biology procedure and techniques, also drive the exonucleases market.
Sectors such as biotechnology, pharmaceuticals, contract research organization, and academic research institutes are the prominent drivers in the market. These sectors are flourishing the market growth by adopting several innovations during the forecast period.
The High costs involved in the development of exonucleases production are likely to hinder the growth of the exonucleases market during the forecast period.
North America dominates the exonucleases market by securing 47.2% of the share during the forecast period. In addition, the presence of a huge well-established molecular biology industry in terms of revenue rapidly boosted the market size in recent years.
The immense pace of research and development activities due to the large presence of biotechnology and pharmaceuticals is increasing the global exonucleases market size. Moreover, favorable government policies aimed at developing these industries flourished in the market during the forecast period.
The Europe region placed second position in the exonucleases market by acquiring 32.5% of the share during the forecast period. Rising new vendors and rising extensive products are propelling the demand for exonucleases in recent years. Although there is a significant increase in genomic organization, the operational mechanism of exonucleases remains an active area of research. Moreover, new techniques such as DNA sequencing and gene expression rapidly rise the region's market. All these factors are accelerating the exonucleases market growth during the forecast period.
All the applications include sequencing, cloning, PCR, restriction digestion, and RFLP. The PCR segment dominates the exonucleases market during the forecast period. In addition, the segment held the largest share, which helps in the diagnosis of hereditary diseases, detect infectious diseases, and identify fingerprints. PCR is used to synthesize new strands in DNA complementary are likely to increase the adoption of PCR applications in recent years.
Start-ups in the exonucleases market industry are now more engaged with launching strategies like targeted marketing, CSR programs, etc., to increase their global prominence. The fact that these businesses are now aiming to handle a certain business-related activity in a nation that offers advantageous legislation is a discernible trend being noted across the board.
This enables start-ups to save expenses while retaining industry experts for each crucial stage of their respective organizations. By cutting trade taxes and duties, governments in developing nations like India, China, Taiwan, and Indonesia, among others, are introducing measures to entice international investors to the corresponding industrial sectors and create more jobs.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
To increase their separate consumer bases, key players in the global exonucleases market are now concentrating more on forming successful joint ventures, acquisitions, and/or collaborations. By being able to serve their assigned target bases both domestically and abroad, companies stand to increase them.
Over the course of the forecast period, it is predicted that this factor, together with promising developments in developing countries from the Asia-Pacific region, including India, China, Taiwan, Indonesia, etc., would greatly increase the commercial opportunities for key players in the global exonucleases market.
Recent Developments in the Exonucleases Market:
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 2.3% from 2022 to 2032 |
Base Year for Estimation | 2021 |
Historical Data | 2017 to 2021 |
Forecast Period | 2022 to 2032 |
Quantitative Units | Revenue in US$ Million and CAGR from 2022 to 2032 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The exonucleases market is predicted to advance at a CAGR of 2.3% from 2022 to 2032.
North America is anticipated to lead the exonucleases market during the forecast period.
The exonucleases market is likely to hold a valuation of US$ 208.1 Million by 2032.
The biotechnological sector is the key driver in the exonucleases market.
1. Executive Summary | Exonucleases Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032
5.3.1. Sequencing
5.3.2. Cloning
5.3.3. Polymerase Chain Reaction (PCR)
5.3.4. Epigenetics
5.3.5. Restriction Digestion
5.3.6. Restriction Fragment Length Polymorphism (RFLP)
5.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
6.3.1. Biotechnological Companies
6.3.2. Pharmaceutical Companies
6.3.3. Contract Research Organizations
6.3.4. Academic Research Institutes
6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Application
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Application
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Application
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Application
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Application
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. India
11.2.1.5. Malaysia
11.2.1.6. Singapore
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of APAC
11.2.2. By Application
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By End User
11.4. Key Takeaways
12. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Application
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States of America
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Application
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Application
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Application
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Application
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Application
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Application
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Application
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Application
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Application
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Application
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Application
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Application
13.12.2.2. By End User
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Application
13.13.2.2. By End User
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Application
13.14.2.2. By End User
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Application
13.15.2.2. By End User
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Application
13.16.2.2. By End User
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Application
13.17.2.2. By End User
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Application
13.18.2.2. By End User
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Application
13.19.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Application
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. QIAGEN N.V.
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.4.1. Marketing Strategy
15.1.2. New England Biolabs
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.4.1. Marketing Strategy
15.1.3. Roche, Ltd
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.4.1. Marketing Strategy
15.1.4. Thermo Fisher Scientific
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.4.1. Marketing Strategy
15.1.5. Takara Bio, Inc
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.4.1. Marketing Strategy
15.1.6. Agilent Technologies, Inc
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.4.1. Marketing Strategy
15.1.7. Affymetrix, Inc
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.4.1. Marketing Strategy
15.1.8. Illumina
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.4.1. Marketing Strategy
15.1.9. Jena Bioscience
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.4.1. Marketing Strategy
15.1.10. Biocompare
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.4.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports